Literature DB >> 1155051

The furosemid test for Menière's disease.

T Futaki, M Kitahara, M Morimoto.   

Abstract

In a previous report it was suggested that intravenous administration of furosemid followed by a comparative caloric test (the furosemid test) could be utilized for detection of endolymphatic hydrops (Kitahara et al., 1973). As a result of the further application of the furosemid test upon 161 patients with vertigo, positive results were observed in 80% of patients with typical Menière's disease, 6% of atypical Menière's disease, 42% with labyrinthine syphilis and 27% with sudden deafness. In patients with labyrinthitis, results were negative. It is thus concluded that the furosemid test provides positive evidence for determining the etiology of vertigo.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155051     DOI: 10.3109/00016487509124706

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  4 in total

1.  European vestibular experiments on the Spacelab-1 mission: 1. Overview.

Authors:  R J von Baumgarten
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

2.  The effect of furosemide on sodium and potassium concentrations in guinea-pig perilymph.

Authors:  N Kanoh; K Makimoto
Journal:  Arch Otorhinolaryngol       Date:  1984

3.  Recent and Frequent Vertigo Attacks Produce Negative Findings on Furosemide-Loading Vestibular Evoked Myogenic Potential Testing in Meniere's Disease.

Authors:  Toru Seo; Ko Shiraishi; Takaaki Kobayashi; Takeshi Fujita; Kazuya Saito; Katsumi Doi
Journal:  Front Neurol       Date:  2018-08-03       Impact factor: 4.003

4.  Endolymphatic volume in patients with meniere's disease and healthy controls: Three-dimensional analysis with magnetic resonance imaging.

Authors:  Taeko Ito; Hiroshi Inui; Toshiteru Miyasaka; Tomoyuki Shiozaki; Akihito Hasukawa; Toshiaki Yamanaka; Kimihiko Kichikawa; Tadashi Kitahara
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-11-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.